Henry Schein, Inc. (Nasdaq: HSIC) announced today the
availability of an antibody rapid blood test, known as Standard Q
COVID-19 IgM/IgG Rapid Test, intended to be administered at the
point of care. The test delivers results within 15 minutes from a
pinprick with no instrumentation required.
Health care professionals can use the results of the test, along
with a patient’s medical history, symptoms, and results of other
relevant testing, to make informed decisions about patient
treatment and care.
Henry Schein is working through multiple channels to distribute
the tests in the United States as quickly as possible in response
to the urgent need for rapid, accurate testing. The Company
anticipates having at least several hundred thousand tests
available by March 30 and significantly increased availability
beginning in April 2020.
The Standard Q COVID-19 test is a rapid immunochromatography
test designed for the qualitative presumptive detection of specific
IgM and IgG antibodies associated with the 2019 novel coronavirus
(SARS-CoV-2) in blood drawn with a pinprick.
Because serology tests measure antibodies, they can help assess
the likelihood of past as well as present infection, and are meant
to be used as an aid to health care professionals in diagnosing the
mid- to later stages of the viral infection. Along with other
information, such as the presence of symptoms, the tests may help
health care professionals assess whether individuals (including
health care workers) have recovered from the virus. Follow-up
testing with a molecular diagnostic should be considered to confirm
or rule out infection.
The Standard Q COVID-19 IgM/IgG Rapid Test is being made
available under emergency guidance issued by the U.S. Food and Drug
Administration (FDA).
“Henry Schein is committed to providing health care
professionals with quality products they can rely on to care for
patients,” said Stanley M. Bergman, Chairman of the Board and Chief
Executive Officer of Henry Schein. “Henry Schein has played a key
role in providing point-of-care testing to health care
professionals, and is now responding to the urgent need for wide
availability of rapid point-of-care testing for COVID-19. This
pandemic is an unprecedented situation, and making rapid diagnostic
tools available to health care professionals is critical for
detecting and mitigating the spread of the coronavirus.”
As the world’s largest distributor of health care solutions to
office-based dental and medical professionals, Henry Schein is
uniquely positioned to distribute the Standard Q COVID-19 test
efficiently. Henry Schein plans to make the Standard Q COVID-19
test available for use by physician offices, hospitals, and other
relevant health care institutions.
The distribution of the kit is part of Henry Schein’s continued
efforts to address pandemic preparedness and response. Among other
efforts, Henry Schein is in direct contact with the World Health
Organization and other multilateral and domestic organizations as
part of Henry Schein’s role as the private-sector lead of the
Pandemic Supply Chain Network, a public-private partnership created
in 2015 to improve the efficiency of the supply chain for personal
protective equipment.
The Standard Q COVID-19 test is manufactured by SD Biosensor,
Inc., a global bio-diagnostic company. SD BioSensor is represented
by VelocityDX in the United States. Henry Schein intends to add
other tests from VelocityDX and other suppliers specific to
COVID-19, with the goal of offering a wide array of point-of-care
tests for health care professionals.
A Q&A addressing the new test and providing additional
information about it is available at
www.henryschein.com/COVID19Statements.
For customers interested in more information about the Standard
Q COVID-19 IgM/IgG Rapid Test, please contact Henry Schein at (844)
211-0140.
To learn more about what Henry Schein is doing to address this
unprecedented situation and the actions the Company is taking to
get more product into the hands of those who need it most – health
care workers – please visit www.henryschein.com/COVID19update.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for
health care professionals powered by a network of people and
technology. With more than 19,000 Team Schein Members worldwide,
the Company's network of trusted advisors provides more than 1
million customers globally with more than 300 valued solutions that
improve operational success and clinical outcomes. Our Business,
Clinical, Technology, and Supply Chain solutions help office-based
dental and medical practitioners work more efficiently so they can
provide quality care more effectively. These solutions also support
dental laboratories, government and institutional healthcare
clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated
distribution network, with a selection of more than 120,000 branded
products and Henry Schein private-brand products in stock, as well
as more than 180,000 additional products available as special-order
items.
A FORTUNE 500 Company and a member of the S&P 500® index,
Henry Schein is headquartered in Melville, N.Y., and has operations
or affiliates in 31 countries. The Company's sales from continuing
operations reached $10.0 billion in 2019, and have grown at a
compound annual rate of approximately 13 percent since Henry Schein
became a public company in 1995.
For more information, visit Henry Schein at www.henryschein.com,
Facebook.com/HenrySchein, and @HenrySchein on Twitter.
Cautionary Note Regarding Forward-Looking Statements
In accordance with the "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995, we provide the following
cautionary remarks regarding important factors that, among others,
could cause future results to differ materially from the
forward-looking statements, expectations and assumptions expressed
or implied herein. All forward-looking statements made by us are
subject to risks and uncertainties and are not guarantees of future
performance. These forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause our
actual results, performance and achievements or industry results to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. These statements are identified by the use of such
terms as "may," "could," "expect," "intend," "believe," "plan,"
"estimate," "forecast," "project," "anticipate," “to be,” “to
make,” “understand or understanding,” or other comparable terms.
Forward looking statements include the number of tests intended to
be made available and the timing for availability, the nature of
the target market, as well as the efficacy or relative efficacy of
the test results given that the test efficacy has not been
independently verified under normal FDA procedures. A full
discussion of our operations and financial condition, status of
litigation matters, including factors that may affect our business
and future prospects, is contained in documents we have filed with
the United States Securities and Exchange Commission, or SEC, and
will be contained in all subsequent periodic filings we make with
the SEC. These documents identify in detail important risk factors
that could cause our actual performance to differ materially from
current expectations.
Risk factors and uncertainties that could cause actual results
to differ materially from current and historical results include,
but are not limited to: effects of a highly competitive and
consolidating market; increased competition by third party online
commerce sites; our dependence on third parties for the manufacture
and supply of our products; our dependence upon sales personnel,
customers, suppliers and manufacturers; our dependence on our
senior management; fluctuations in quarterly earnings; risks from
expansion of customer purchasing power and multi-tiered costing
structures; increases in shipping costs for our products or other
service issues with our third-party shippers; general global
macro-economic conditions; risks associated with currency
fluctuations; risks associated with political and economic
uncertainty; disruptions in financial markets; volatility of the
market price of our common stock; changes in the health care
industry; implementation of health care laws; failure to comply
with regulatory requirements and data privacy laws; risks
associated with our global operations; risks associated with the
Novel Coronavirus Disease 2019 (COVID-19); risk associated with the
United Kingdom's withdrawal from the European Union; transitional
challenges associated with acquisitions, dispositions and joint
ventures, including the failure to achieve anticipated
synergies/benefits; financial and tax risks associated with
acquisitions, dispositions and joint ventures; litigation risks;
new or unanticipated litigation developments and the status of
litigation matters; the dependence on our continued product
development, technical support and successful marketing in the
technology segment; our dependence on third parties for certain
technologically advanced components; risks from disruption to our
information systems; cyberattacks or other privacy or data security
breaches; certain provisions in our governing documents that may
discourage third-party acquisitions of us; and changes in tax
legislation. The order in which these factors appear should not be
construed to indicate their relative importance or priority.
We caution that these factors may not be exhaustive and that
many of these factors are beyond our ability to control or predict.
Accordingly, any forward-looking statements contained herein should
not be relied upon as a prediction of actual results. We undertake
no duty and have no obligation to update forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200326005310/en/
Investors Steven Paladino Executive Vice President and Chief
Financial Officer steven.paladino@henryschein.com (631)
843-5500
Carolynne Borders Vice President, Investor Relations
carolynne.borders@henryschein.com (631) 390-8105
Media Ann Marie Gothard Vice President, Corporate Media
Relations annmarie.gothard@henryschein.com (631) 390-8169
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Henry Schein (NASDAQ:HSIC)
Historical Stock Chart
From Sep 2023 to Sep 2024